<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="48021">Peptide nucleic acids</z:chebi> (<z:chebi fb="3" ids="48021">PNAs</z:chebi>) are synthetic homolog of nucleic acids in which the phosphate-sugar <z:chebi fb="1" ids="15986">polynucleotide</z:chebi> backbone is replaced by a flexible <z:chebi fb="13" ids="53224">polyamide</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>They bind complementary <z:chebi fb="1" ids="15986">polynucleotide</z:chebi> sequences with higher affinity and specificity than their natural counterparts </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="3" ids="48021">PNAs</z:chebi> linked to the appropriate nuclear localization signal (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NLS</z:e>) <z:chebi fb="7" ids="16670">peptide</z:chebi> have been used to selectively down-regulate the expression of several genes in viable cells </plain></SENT>
<SENT sid="3" pm="."><plain>For example in Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cells the c-myc oncogene is translocated in proximity to the Emu enhancer of the Ig gene locus and upregulated </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="3" ids="48021">PNAs</z:chebi> complementary to the second exon of c-myc or to the Emu enhancer sequence (PNAEmu-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NLS</z:e>), selectively and specifically block the expression of the c-myc oncogene and inhibit cell growth in vitro and in vivo </plain></SENT>
<SENT sid="5" pm="."><plain>PNAEmu-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NLS</z:e> administration to mice did not exhibit toxic effects even at the highest concentration allowed by the experimental conditions </plain></SENT>
<SENT sid="6" pm="."><plain>Because of the accumulating data confirming PNAEmu-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NLS</z:e> potential therapeutic value, PNAEmu-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NLS</z:e> was evaluated for the inability to induce mutations in tester strains of Salmonella typhimurium, Escherichia coli, and at the hprt locus in Chinese hamster ovary cells (<z:chebi fb="0" ids="29327">CHO</z:chebi>) </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, the induction of chromosomal aberrations in <z:chebi fb="0" ids="29327">CHO</z:chebi> cells and of micronuclei in human lymphocytes were investigated </plain></SENT>
<SENT sid="8" pm="."><plain>We may conclude that PNAEmu-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NLS</z:e> neither induces mutations nor has clastogenic effects as detectable by treatment under the standard test conditions </plain></SENT>
</text></document>